Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Cargo loading after curing
What ifWhat if the gel took up cargo only after curing?
Claim language“hydrogel precursor comprising the cargo”
A cargo-free alginate precursor forms a coating when exposed to calcium ions. A separate catheter then delivers an aqueous cargo solution over the cured coating, where the cargo diffuses into the gel and partitions back into luminal fluid over time.
1.2Delivery through the outer wall
What ifWhat if a needle deposited the precursor beneath the epithelium from the outer surface of the tube?
Claim language“through a lumen”
During surgical exposure, a needle enters the outer wall and deposits a cargo-containing fibrin precursor in the submucosa. The fibrin sets at the injection site, and released soluble cargo diffuses toward the basal side of the epithelium.
1.3Placement of a preformed sleeve
What ifWhat if the delivery step placed a fully formed cargo-loaded hydrogel sleeve against the epithelium?
Claim language“curing the hydrogel precursor”
A molded gelatin hydrogel sleeve takes up soluble cargo from an aqueous bath before placement. A collapsed balloon catheter carries the hydrated sleeve through the lumen and expands it against the epithelial wall, where the sleeve releases cargo as the gelatin erodes.
1.4Diffusion through an intact gel
What ifWhat if cargo diffused out while the gel network stayed intact throughout the release period?
Claim language“the hydrogel degrades over time”
A removable catheter tip holds a covalently crosslinked polyvinyl alcohol gel loaded with soluble cargo. The cargo diffuses through the water-filled gel network and exits through openings in the tip facing the epithelium.
1.4Release by ion exchange
What ifWhat if ions in luminal fluid displaced cargo bound within an intact gel?
Claim language“the hydrogel degrades over time”
A crosslinked hydrogel with fixed sulfonate groups holds a positively charged small-molecule cargo. Sodium ions in luminal fluid exchange with the bound cargo, allowing it to diffuse to the epithelial surface while the polymer network stays intact.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Component substitution
Enzymatic curing of a gelatin coating
Microbial transglutaminase replaces the light source and photoinitiator. Separate channels carry an aqueous gelatin precursor containing a fluorescent tracer and a solution of the enzyme to a short mixer at the applicator tip. The applicator transfers the mixture onto the luminal surface, where the enzyme crosslinks the gelatin. Proteolytic cleavage breaks down the gelatin network and releases the tracer at the epithelial surface.
Parameter or scale variation
Segmented coating with open flow paths
In an excised intestinal segment with an approximately 10 mm inner diameter, a contact applicator deposits three 5 mm bands of tracer-loaded precursor separated by 5 mm gaps. A removable 9 mm diameter mandrel centers the lumen and sets a nominal radial coating thickness of 0.5 mm during curing. After curing, the mandrel slides out and exposes a continuous central flow path. The bands erode under perfusion and release the tracer at three axial positions.
Combination with existing systems
Endoscopic placement using a contact applicator
A flexible endoscope carries a catheter with a soft contact pad through its working channel. The operator advances the pad into the lumen and draws it across the target epithelium while the catheter feeds tracer-loaded precursor to the pad. An optical fiber beside the feed channel illuminates the deposited layer as the pad moves clear. The coating erodes in place and releases the tracer against the epithelium.
Paired perfusion for tracer release measurement
A perfusion chamber mounts an excised tubular epithelial segment between fittings and supplies fluid independently to its lumen and outer surface. A side port on the inlet fitting admits an applicator that deposits tracer-loaded precursor on the luminal wall for in-place curing. Separate fraction collectors sample the luminal and outer fluid circuits as the gel erodes. Fluorescence measurements track tracer carried downstream and tracer recovered on the outer side of the tissue.
Automated or data-driven variant
Image-guided control of coating coverage
A motorized stage positions a contact dispenser and curing light inside an excised intestinal segment, and a camera images the luminal surface. Software uses calibrated fluorescence from the tracer to map the deposited precursor and directs the dispenser to fill gaps within a selected region. The controller pauses dispensing during each image capture and activates the curing light once the region reaches the programmed coverage threshold. During perfusion, the camera records changes in coating area as the gel erodes and releases the tracer.
Specific version of a part
Suspended cargo in alginate
An aqueous sodium alginate solution contains cargo entrapped in phospholipid vesicles. Gentle mixing distributes the vesicles through the precursor before transfer to the delivery syringe.
Circumferential application by catheter
A flexible catheter passes through the lumen to the target segment. Radial outlets near its tip deposit the cargo-containing precursor around the inner wall as the catheter is withdrawn.
Visible light curing through fiber
The cargo-containing precursor contains polyethylene glycol diacrylate and a photoinitiator responsive to violet light. A side-emitting optical fiber illuminates the deposited layer at approximately 405 nanometers to crosslink the precursor around the cargo.
Cargo release by ester hydrolysis
A cargo-loaded polyethylene glycol hydrogel has ester bonds in the strands between crosslinks. Water cleaves those bonds over time, increasing the network mesh size and releasing entrapped cargo into fluid at the epithelial surface.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a) preparing a hydrogel precursor comprising the cargo;
A kit for preparing a hydrogel contains a dual liquid applicator, plunger cap, spray tips, syringe holder, as well as a syringe containing trilysine dissolved in a phosphate buffer moiety, a syringe containing a borate buffer moiety, a vial containing PEG and FD&C Blue #1 in powder form, and a vial containing Bupivacaine hydrochloride.
A · US 2011/0091549 A1 · ¶ 72
However, SVA-II 110 incorporates heater 106 that is embedded inside hydrogel precursor 102 prior to polymerization.
B · US 2021/0284775 A1 · ¶ 50
1.2b) applying the hydrogel precursor to the tubular epithelial structure through a lumen of said tubular epithelial structure; and
The hydrogel may also be applied as a bolus that fills a void or lumen and/or as a coating that conforms to a tissue surface or to a three dimensional shape.
A · US 2011/0091549 A1 · ¶ 7
1.3c) curing the hydrogel precursor, thereby forming a hydrogel comprising the cargo;
In general, this may be accomplished by having a precursor that can be activated at the time of application to a tissue to form a crosslinked hydrogel.
A · US 2011/0091549 A1 · ¶ 40
The heaters can be embedded in the precursor solution and the gel polymerized using UV light.
B · US 2021/0284775 A1 · ¶ 43
1.4wherein the hydrogel degrades over time, thereby releasing the cargo to the tubular epithelial structure.
Drugs may be released by diffusion through the hydrogel to the surrounding tissue, degradation of the hydrogel itself, or a combination of both diffusion and degradation.
A · US 2011/0091549 A1 · ¶ 4
An empty cell means only that no passage was reproduced there.
Statements in these documents
For drug delivery, prolonged or expedited release may be difficult to achieve in a controlled manner.
A · US 2011/0091549 A1 · ¶ 3
It would be advantageous to modulate drug release profiles without any manipulation of the drug molecule or compound, and without the use of excipients.
A · US 2011/0091549 A1 · ¶ 4
Practical soft robotic applications having localized and time-varying deformations of responsive hydrogels have been difficult to realize.
B · US 2021/0284775 A1 · ¶ 5
This approach allows for controlling many degrees of freedom in the material to create complex motion trajectories.
B · US 2021/0284775 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355254 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355254/, SHA-256 3e1e575d3b0b48e382ed1ee40bd604a53517510780b0e8c61711d7fcf52ebbd9